Baxter International Inc. (NYSE:BAX) Stake Held by Glenview State Bank Trust DEPT.

Glenview State Bank Trust DEPT. continued to hold its position in shares of Baxter International Inc. (NYSE:BAX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,223 shares of the medical instruments supplier’s stock at the end of the second quarter. Glenview State Bank Trust DEPT.’s holdings in Baxter International were worth $317,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Reilly Financial Advisors LLC boosted its position in shares of Baxter International by 20.4% in the first quarter. Reilly Financial Advisors LLC now owns 2,054 shares of the medical instruments supplier’s stock worth $107,000 after buying an additional 348 shares during the period. Quadrant Capital Group LLC raised its stake in shares of Baxter International by 1.3% in the first quarter. Quadrant Capital Group LLC now owns 2,344 shares of the medical instruments supplier’s stock worth $113,000 after buying an additional 31 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its stake in shares of Baxter International by 6.1% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 2,533 shares of the medical instruments supplier’s stock worth $131,000 after buying an additional 145 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its stake in shares of Baxter International by 3.9% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,776 shares of the medical instruments supplier’s stock worth $144,000 after buying an additional 103 shares in the last quarter. Finally, Trust Co. of Vermont raised its stake in shares of Baxter International by 8.7% in the first quarter. Trust Co. of Vermont now owns 3,282 shares of the medical instruments supplier’s stock worth $170,000 after buying an additional 262 shares in the last quarter. 85.08% of the stock is currently owned by institutional investors and hedge funds.

Baxter International Inc. (NYSE:BAX) traded up 0.22% during midday trading on Friday, reaching $59.84. 2,213,852 shares of the company’s stock traded hands. The company’s 50-day moving average price is $60.89 and its 200-day moving average price is $55.35. The stock has a market cap of $32.61 billion, a P/E ratio of 36.31 and a beta of 0.66. Baxter International Inc. has a 52-week low of $43.13 and a 52-week high of $63.14.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Wednesday, July 26th. The medical instruments supplier reported $0.63 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.57 by $0.06. Baxter International had a net margin of 8.85% and a return on equity of 14.82%. The company had revenue of $2.61 billion for the quarter, compared to the consensus estimate of $2.59 billion. During the same quarter in the prior year, the company earned $0.46 EPS. Baxter International’s quarterly revenue was up .8% on a year-over-year basis. On average, equities analysts predict that Baxter International Inc. will post $2.39 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 2nd. Stockholders of record on Friday, September 1st will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Wednesday, August 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 1.07%. Baxter International’s payout ratio is 38.79%.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by BNB Daily and is the property of of BNB Daily. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/14/glenview-state-bank-trust-dept-has-317000-stake-in-baxter-international-inc-nysebax-updated-updated-updated.html.

A number of analysts have weighed in on the stock. Leerink Swann restated an “outperform” rating and issued a $75.00 target price (up previously from $67.00) on shares of Baxter International in a research report on Thursday, July 27th. Cowen and Company reiterated a “market perform” rating and set a $68.00 price target (up previously from $66.00) on shares of Baxter International in a report on Thursday, July 27th. Cantor Fitzgerald set a $70.00 price target on shares of Baxter International and gave the stock a “buy” rating in a report on Wednesday, July 26th. UBS AG lifted their price target on shares of Baxter International from $57.00 to $62.00 and gave the stock a “neutral” rating in a report on Friday, July 28th. Finally, Zacks Investment Research lowered shares of Baxter International from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $65.33.

In other news, Director Carole J. Shapazian sold 2,618 shares of the firm’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $57.92, for a total transaction of $151,634.56. Following the sale, the director now owns 9,848 shares of the company’s stock, valued at approximately $570,396.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.05% of the stock is owned by company insiders.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply